FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887116323> ?p ?o ?g. }

• W2887116323 endingPage "5005" @default.
• W2887116323 startingPage "5005" @default.
• W2887116323 abstract "5005 Background: Presence of the AR-V7 splice variant may predict resistance to Enz and abiraterone in men with mCRPC. Gal is an oral agent that disrupts AR signaling via AR degradation, CYP17 lyase inhibition, and AR antagonism. ARMOR3-SV was designed to test the hypothesis that in mCRPC patients with AR-V7+ CTCs, Gal could improve radiographic progression-free survival (rPFS) versus Enz. Methods: In this randomized, open-label, multicenter phase 3 study (NCT02438007), men with treatment-naïve mCRPC were screened for CTC-specific AR-V7 (Qiagen), and AR-V7+ men were randomized 1:1 to Gal or Enz. rPFS (by independent blinded central review) was the primary endpoint. Planned sample size was 148, with 120 rPFS events to achieve 90% power to detect a hazard ratio of ≤0.55. Results: 953 patients were screened globally for AR-V7 from Sept 2015 through study closure; 73 men (8%; 95% CI 6-10%) were AR-V7+, 250 (26%) AR-V7–, and 630 (66%) had no CTCs/AR present (unevaluable). AR-V7 detection was associated with higher PSA levels ( > vs < median; P < 0.01), more bone metastases ( > 20 vs 11-20 vs 6-10 vs 0-5; P < 0.01), presence of M1 disease at diagnosis (dx) (yes vs no; P = 0.04), shorter time from dx to screening ( < vs > median; P < 0.01), higher ECOG (≥1 vs 0; P = 0.02), prior antiandrogen use (yes vs no; P < 0.01) and prior docetaxel use (yes vs no; P < 0.01). Among the AR-V7+ men, 38 were randomized (19 Gal, 19 Enz), 31 screen failed, and 4 were discontinued from screening at study halt. Baseline characteristics were balanced. On the recommendation of the DSMB, the study was closed early as it was unlikely to meet its primary endpoint. At the time of the study closure, in the Gal and Enz arms respectively, median time on therapy was 2.0 vs 2.8 mo, median time to PSA progression (PCWG1) was 3.9 vs 3.8 mo, PSA 50 response rates in evaluable patients were 2/16 (13%) and 8/19 (42%), and there were no new safety signals. Conclusions: In treatment-naïve mCRPC patients, AR-V7 detection is more common in men with higher disease burden and portends a poor prognosis. Novel study designs and alternative treatment approaches are urgently needed for AR-V7+ mCRPC patients. Clinical trial information: NCT02438007." @default.
• W2887116323 created "2018-08-22" @default.
• W2887116323 creator A5023517416 @default.
• W2887116323 creator A5046598144 @default.
• W2887116323 creator A5053749991 @default.
• W2887116323 creator A5057407696 @default.
• W2887116323 creator A5061815866 @default.
• W2887116323 creator A5070922234 @default.
• W2887116323 creator A5075880342 @default.
• W2887116323 creator A5077552075 @default.
• W2887116323 date "2017-05-20" @default.
• W2887116323 modified "2023-10-14" @default.
• W2887116323 title "Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC)." @default.
• W2887116323 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.5005" @default.
• W2887116323 hasPublicationYear "2017" @default.
• W2887116323 type Work @default.
• W2887116323 sameAs 2887116323 @default.
• W2887116323 citedByCount "21" @default.
• W2887116323 countsByYear W28871163232017 @default.
• W2887116323 countsByYear W28871163232018 @default.
• W2887116323 countsByYear W28871163232019 @default.
• W2887116323 countsByYear W28871163232020 @default.
• W2887116323 countsByYear W28871163232021 @default.
• W2887116323 crossrefType "journal-article" @default.
• W2887116323 hasAuthorship W2887116323A5023517416 @default.
• W2887116323 hasAuthorship W2887116323A5046598144 @default.
• W2887116323 hasAuthorship W2887116323A5053749991 @default.
• W2887116323 hasAuthorship W2887116323A5057407696 @default.
• W2887116323 hasAuthorship W2887116323A5061815866 @default.
• W2887116323 hasAuthorship W2887116323A5070922234 @default.
• W2887116323 hasAuthorship W2887116323A5075880342 @default.
• W2887116323 hasAuthorship W2887116323A5077552075 @default.
• W2887116323 hasConcept C121608353 @default.
• W2887116323 hasConcept C126322002 @default.
• W2887116323 hasConcept C126894567 @default.
• W2887116323 hasConcept C143998085 @default.
• W2887116323 hasConcept C168563851 @default.
• W2887116323 hasConcept C203092338 @default.
• W2887116323 hasConcept C207103383 @default.
• W2887116323 hasConcept C2775832370 @default.
• W2887116323 hasConcept C2776421732 @default.
• W2887116323 hasConcept C2776551883 @default.
• W2887116323 hasConcept C2777899217 @default.
• W2887116323 hasConcept C2780192828 @default.
• W2887116323 hasConcept C2781190966 @default.
• W2887116323 hasConcept C44249647 @default.
• W2887116323 hasConcept C61367390 @default.
• W2887116323 hasConcept C71924100 @default.
• W2887116323 hasConceptScore W2887116323C121608353 @default.
• W2887116323 hasConceptScore W2887116323C126322002 @default.
• W2887116323 hasConceptScore W2887116323C126894567 @default.
• W2887116323 hasConceptScore W2887116323C143998085 @default.
• W2887116323 hasConceptScore W2887116323C168563851 @default.
• W2887116323 hasConceptScore W2887116323C203092338 @default.
• W2887116323 hasConceptScore W2887116323C207103383 @default.
• W2887116323 hasConceptScore W2887116323C2775832370 @default.
• W2887116323 hasConceptScore W2887116323C2776421732 @default.
• W2887116323 hasConceptScore W2887116323C2776551883 @default.
• W2887116323 hasConceptScore W2887116323C2777899217 @default.
• W2887116323 hasConceptScore W2887116323C2780192828 @default.
• W2887116323 hasConceptScore W2887116323C2781190966 @default.
• W2887116323 hasConceptScore W2887116323C44249647 @default.
• W2887116323 hasConceptScore W2887116323C61367390 @default.
• W2887116323 hasConceptScore W2887116323C71924100 @default.
• W2887116323 hasIssue "15_suppl" @default.
• W2887116323 hasLocation W28871163231 @default.
• W2887116323 hasOpenAccess W2887116323 @default.
• W2887116323 hasPrimaryLocation W28871163231 @default.
• W2887116323 hasRelatedWork W122177069 @default.
• W2887116323 hasRelatedWork W2135620818 @default.
• W2887116323 hasRelatedWork W2408333324 @default.
• W2887116323 hasRelatedWork W2568045406 @default.
• W2887116323 hasRelatedWork W2590124563 @default.
• W2887116323 hasRelatedWork W2770702948 @default.
• W2887116323 hasRelatedWork W2982156914 @default.
• W2887116323 hasRelatedWork W3135865861 @default.
• W2887116323 hasRelatedWork W3181573761 @default.
• W2887116323 hasRelatedWork W4229076799 @default.
• W2887116323 hasVolume "35" @default.
• W2887116323 isParatext "false" @default.
• W2887116323 isRetracted "false" @default.
• W2887116323 magId "2887116323" @default.
• W2887116323 workType "article" @default.